TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04045210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Support Based on Positive Suggestions
Description: Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
Study: NCT02044458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stylette
Description: use of stylette for successful insertion of foley catheter for induction of labor
Study: NCT01656928

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: preschool-based nutritional intervention
Description: 6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: preschool-based nutritional intervention
Description: 6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
Study: NCT03104647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRP-Clinic
Description: Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
Study: NCT02493049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Addition of Domperidone to current Disease Modifying Therapy.
Study: NCT03768765

Intervention type: PROCEDURE
Intervention: Holmium Laser Prostate Surgery
Description: Patients will undergo standard of care holmium laser prostate surgery

Intervention type: PROCEDURE
Intervention: Holmium Laser Prostate Surgery
Description: Patients will undergo standard of care holmium laser prostate surgery
Study: NCT03539770

Intervention type: PROCEDURE
Intervention: Posterior spinal fusion
Description: Surgical procedure that involves placement of spinal rods to correct spinal curvature
Study: NCT04612855

Intervention type: OTHER
Intervention: Groupwise comparison of primary and secondary outcomes
Description: Statistical comparison of cohorts. Cfr supporting information on statistical plan.

Intervention type: OTHER
Intervention: Groupwise comparison of primary and secondary outcomes
Description: Statistical comparison of cohorts. Cfr supporting information on statistical plan.
Study: NCT04104724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help
Description: self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
Study: NCT02134249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin
Description: 2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
Study: NCT00978250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
Description: FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
Study: NCT03912649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RemovAid
Description: The RemovAid device is used for removal
Study: NCT00166361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memokath 051 Ureteral Stent
Description: The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JJ Stent
Description: A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
Study: NCT00240682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
Study: NCT02661802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen Supplementation
Description: Oxygen delivery was continuous by mask at 40%
Study: NCT02542839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroStar TMS therapy
Description: Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NeuroStar TMS therapy
Description: Same procedure as real rTMS without stimulating the cerebral cortex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
Description: All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
Description: All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniocervical Dystonia Questionnaire (CDQ-24)
Description: All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Craniocervical Dystonia Questionnaire (CDQ-24)
Description: All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebellar-brain Inhibition (CBI)
Description: All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
Study: NCT03344367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR029
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
Study: NCT01957488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product 1
Description: Coloplast Test product 1 is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product 1
Description: Coloplast Test product 1 is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product 1
Description: Coloplast Test product 1 is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product 2
Description: Coloplast Test product 2 is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product 2
Description: Coloplast Test product 2 is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product 2
Description: Coloplast Test product 2 is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast SenSura
Description: SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast SenSura
Description: SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast SenSura
Description: SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
Study: NCT03086772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light Exercise
Description: Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
Study: NCT03407859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sequential Treatment With different CART
Description: Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL
Study: NCT01073995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog and Sensorcaine
Description: Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
Study: NCT02829723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ945
Description: BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ945
Description: BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)
Study: NCT01073995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Kenalog and Sensorcaine
Description: Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
Study: NCT01968798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg enteric-coated aspirin, taken daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg enteric-coated placebo, taken daily
Study: NCT00814099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team approach to sedation management
Description: The team approach to sedation management includes the following:~* Team education and consensus on the use of sedatives~* Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~* A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~* Team feedback on sedation management performance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual approach to sedation management
Description: The pediatric ICU will continue its usual approach to sedation management.
Study: NCT02259751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL
Study: NCT02542839

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cerebellar-brain Inhibition (CBI)
Description: All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Description: All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Botulinum toxin injections
Description: All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
Study: NCT03007784

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) / Comparison of current intensities

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) / Comparison of current intensities
Study: NCT00546325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets. Once daily before breakfast
Study: NCT04133103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: first ambulation at 4 hour after operation
Description: Two groups were conducted for first ambulation at 4 or 24 hours aftër operation
Study: NCT02867514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
Study: NCT01500564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS (device) Eldith DC-Stimulator
Description: tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
Study: NCT06285669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping application
Description: kinesiotaping application
Study: NCT00803101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Beriplex® P/N (Kcentra)
Description: Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh frozen plasma
Description: Intravenous infusion, dosage depending on baseline INR and body weight
Study: NCT02473861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
Study: NCT02354716

Intervention type: DEVICE
Intervention: EndoFLIP
Description: The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions \& function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- \& post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, \& what characteristics determine \& predict refractory \& recurrent strictures.
Study: NCT03503539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini percutaneous nephrolithotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde intrarenal surgery
Study: NCT01679301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Dose (Sleep Mode)
Description: SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Dose
Description: SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
Study: NCT00791323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 0.4%
Description: One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubricating Eye Drop
Description: One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
Study: NCT02827318

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Description: 75g Isomaltulose (low glycaemic load intervention)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 75g Glucose (high glycaemic load intervention)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sweetened water
Description: Sweetened water will be used as a control
Study: NCT04672096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronoff BASMATI Injectrode
Description: The 28 day temporary placement of a Basmati Injectrode does not result in unexpected levels of inflammation or encapsulation.
Study: NCT01119014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: pill, 2,5-20 mg/day, maximum 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: pill, 50-600mg/day, maximum 16 weeks
Study: NCT00792558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-817378
Description: Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
Study: NCT03091673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: 0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: 0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
Study: NCT00610974

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body-weight supported treadmill training
Description: BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training
Description: BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
Study: NCT03812211

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Supplement
Description: Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement
Study: NCT04872244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele
Description: usage of mirena ( levonorgestrel releasing intrauterine device) in isthmocele for postmenstrual spotting and do not have desire for fertility

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Drug Implant Product
Description: intrauterine administration
Study: NCT00659594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 200µg Ciclesonide versus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo